Fairvalue-Calculator Fairvalue-Calculator
EN DE

REGENXBIO Inc (RGNX) Fair Value & Analysis

Healthcare · US · Market cap $459M

Price$9.95
Fair Value$8.94
Upside-10.2%
Quality95/100
Evidence: Low Range $6.71 – $11.18

Fair value as of: Jun 24, 2026

Analysis

REGENXBIO Inc (RGNX) currently trades at $9.95, while our model-based Fair Value estimate is $8.94 — implying the stock looks roughly 10.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United Sta…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is REGENXBIO Inc (RGNX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $8.94 versus a price of $9.95 — about −10% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RGNX?
Our 21-model fair value for REGENXBIO Inc is $8.94 (as of Jun 24, 2026), built from audited fundamentals. The current price is $9.95.
What is the quality score of RGNX?
REGENXBIO Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.